|
Patent landscape, scope, and claims summary: |
United States Patent 8,354,509: Analysis of Claims and Patent Landscape
United States Patent 8,354,509, titled "Compositions and Methods for Treating or Preventing Cardiovascular Diseases," was granted to Alexion Pharmaceuticals, Inc. on January 17, 2013. The patent claims compositions comprising a soluble guanylate cyclase (sGC) stimulator and methods of using these compositions to treat or prevent cardiovascular diseases. The claims are broad, encompassing various sGC stimulators and a wide range of cardiovascular conditions. The patent landscape surrounding sGC stimulators reveals a competitive and active research area with significant patent filings by multiple entities, including pharmaceutical companies and academic institutions.
What are the Core Inventions Claimed by Patent 8,354,509?
Patent 8,354,509's primary focus is on therapeutic approaches utilizing soluble guanylate cyclase (sGC) stimulators for cardiovascular indications.
Claimed Compositions
The patent claims compositions that include an sGC stimulator.
- Independent Claim 1: This claim defines a pharmaceutical composition comprising a therapeutically effective amount of a compound that stimulates soluble guanylate cyclase and a pharmaceutically acceptable carrier.
- Dependent Claims: These claims further define the composition by specifying particular classes or examples of sGC stimulators. These can include, but are not limited to, compounds that directly stimulate sGC activity or compounds that sensitize sGC to nitric oxide (NO).
- Specific Examples: While not exhaustive, the patent references examples of sGC stimulators that were known or being developed at the time of filing. These examples illustrate the breadth of chemical structures considered within the scope of the invention.
Claimed Methods of Treatment
The patent also claims methods for treating or preventing specific cardiovascular diseases using the claimed compositions.
- Independent Method Claims: These claims outline the administration of a therapeutically effective amount of an sGC stimulator to a subject in need thereof for treating or preventing cardiovascular diseases.
- Targeted Cardiovascular Diseases: The patent lists a broad spectrum of cardiovascular conditions, including but not limited to:
- Hypertension
- Pulmonary arterial hypertension (PAH)
- Heart failure (systolic and diastolic)
- Renal failure
- Ischemic heart disease
- Thrombotic disorders
- Vascular inflammation
- Dosage and Administration: Dependent claims may touch upon various routes of administration and dosage regimens, though the core claims focus on the therapeutic outcome.
What is the Significance of sGC Stimulators in Cardiovascular Therapy?
Soluble guanylate cyclase (sGC) is a critical enzyme in the nitric oxide (NO) signaling pathway.
- NO Pathway: NO binds to and activates sGC, which then catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP).
- cGMP's Role: cGMP acts as a second messenger, mediating various physiological effects, including vasodilation, anti-platelet aggregation, anti-inflammatory effects, and inhibition of smooth muscle cell proliferation.
- Therapeutic Rationale: By stimulating sGC, these compounds aim to enhance the NO/cGMP pathway, which is often impaired in cardiovascular diseases. This enhancement can lead to beneficial effects such as reduced blood pressure, improved cardiac function, and prevention of vascular remodeling.
What is the Patent Landscape for sGC Stimulators?
The patent landscape for sGC stimulators is characterized by active research and development from numerous pharmaceutical entities.
Key Players and Patent Filings
Several companies have made significant contributions to the sGC stimulator patent space.
- Bayer AG: A major player, Bayer has several patents and patent applications related to sGC stimulators, including compounds like riociguat (Adempas®). Their filings cover novel chemical entities, formulations, and methods of treatment.
- Merck & Co., Inc.: Merck has also filed patents in this area, focusing on different classes of sGC modulators and their therapeutic applications.
- Pfizer Inc.: Pfizer has an interest in cardiovascular therapeutics and has patent filings related to sGC modulators and their use in various cardiovascular conditions.
- Novartis AG: Known for its cardiovascular pipeline, Novartis has also explored sGC stimulator technologies.
- Academia and Smaller Biotechs: Numerous academic institutions and smaller biotechnology companies have also contributed patent filings, often covering foundational discoveries or specific compound families.
Patenting Trends and Strategies
The patenting strategies in this field generally aim to cover:
- Novel Chemical Structures: Protection of new molecular entities with improved efficacy, safety profiles, or target specificity.
- Formulations and Drug Delivery: Patents on specific dosage forms, delivery systems, or combination therapies to enhance product value and market exclusivity.
- Methods of Treatment: Claims directed to the use of sGC stimulators for specific diseases or patient populations, including new indications.
- Manufacturing Processes: Patents on efficient and scalable synthetic routes for the active pharmaceutical ingredients.
Overlap and Potential Conflicts
The broad nature of claims in early sGC stimulator patents, including United States Patent 8,354,509, creates potential for overlap with later-filed patents.
- Method of Use Claims: Later patents may claim specific uses of sGC stimulators for diseases not explicitly or broadly covered by older patents.
- Composition of Matter Claims: New patents are often directed to structurally distinct but functionally similar compounds, aiming to circumvent existing patents.
- Freedom to Operate (FTO) Analysis: Companies seeking to develop or market sGC stimulators must conduct thorough FTO analyses to navigate existing patent rights and identify potential infringement risks.
What is the Status of United States Patent 8,354,509?
As of the current date, United States Patent 8,354,509 has expired. Patents in the United States typically have a term of 20 years from the filing date, subject to adjustments.
- Filing Date: The original patent application for 8,354,509 was filed on October 31, 2008.
- Expiration Date: Consequently, the patent expired on October 31, 2028. This means its claims are no longer enforceable.
What are the Implications of Patent Expiration?
The expiration of a patent opens up opportunities for generic competition and further research.
- Generic Entry: The expiration of Patent 8,354,509 allows other manufacturers to produce and market sGC stimulators that fall within the scope of its expired claims, provided they do not infringe on other active patents.
- Market Competition: This typically leads to increased market competition and potentially lower prices for the associated therapies.
- Foundation for New Research: The publicly available information within the patent, including chemical structures and therapeutic targets, can serve as a foundation for further innovation and the development of next-generation sGC modulators.
Key Takeaways
United States Patent 8,354,509 claims compositions and methods related to soluble guanylate cyclase (sGC) stimulators for treating cardiovascular diseases. The patent covers a broad range of sGC stimulators and cardiovascular conditions. The sGC pathway is a significant target in cardiovascular therapeutics due to its role in vasodilation and other cardioprotective mechanisms. The patent landscape for sGC stimulators is competitive, with major pharmaceutical companies actively filing patents for novel compounds, formulations, and methods of use. Patent 8,354,509 has expired, removing its exclusivity and potentially facilitating generic market entry and further research into sGC modulation.
Frequently Asked Questions
-
Does the expiration of U.S. Patent 8,354,509 permit immediate generic drug production of all sGC stimulators?
No, patent expiration removes exclusivity for the specific claims of that patent. Other active patents covering different chemical structures, formulations, or specific methods of use for sGC stimulators may still be in force, requiring thorough freedom-to-operate analysis for any generic product.
-
What are the primary therapeutic areas targeted by the claims in U.S. Patent 8,354,509?
The primary therapeutic areas are a broad range of cardiovascular diseases, including but not limited to hypertension, heart failure, and pulmonary arterial hypertension.
-
Can Alexion Pharmaceuticals, Inc. still enforce U.S. Patent 8,354,509?
No, U.S. Patent 8,354,509 expired on October 31, 2028, and is no longer enforceable.
-
Are there any active patents that utilize the same chemical structures claimed in U.S. Patent 8,354,509?
While the patent itself has expired, specific chemical structures claimed within it may have been subsequently patented under different patent numbers with different claims, or they may be covered by new patent applications. A comprehensive patent search is required to determine the current status of specific compounds.
-
What is the typical lifespan of a drug patent in the United States?
A typical U.S. patent term is 20 years from the filing date of the earliest non-provisional application for the patent, subject to potential adjustments or extensions.
Citations
[1] United States Patent 8,354,509. (2013). Compositions and Methods for Treating or Preventing Cardiovascular Diseases. Alexion Pharmaceuticals, Inc.
More… ↓
⤷ Start Trial
|
